Key facts
- It has raised $261.1M across 1 recorded rounds; the latest was Later Stage VC (Series C) ($175.0M) in Oct 2024.
- Notable investors include Andreessen Horowitz, General Catalyst, Lightspeed Venture Partners, RA Capital Management, Digitalis Ventures — 17 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Alpha-9 Oncology
Funding rounds
1 roundsAbout Alpha-9 Oncology
Operator of a radiopharmaceutical company intended to improve the diagnosis and treatment of metastatic cancer. The company develops imaging and therapeutic molecules for solid and hematologic malignancies by using proprietary technology, enabling healthcare professionals to give patients differentiated molecules with the potential to extend their lives with favorable safety profiles.
- Industry
- Biotechnology
- Sector
- Healthcare
- HQ
- Vancouver, Canada
- Founded
- 2018
- Employees
- 78
- Website
- a9oncology.com/
- Ownership
- Privately Held (backing)
Alpha-9 Oncology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Alpha-9 Oncology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Alpha-9 Oncology in its N-PORT filings yet. We sweep new filings monthly.